These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 7915910)
1. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Sykes E; Woodburn K; Decker D; Kessel D Br J Cancer; 1994 Sep; 70(3):401-4. PubMed ID: 7915910 [TBL] [Abstract][Full Text] [Related]
2. Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteins. Woodburn K; Sykes E; Kessel D Int J Biochem Cell Biol; 1995 Jul; 27(7):693-9. PubMed ID: 7648425 [TBL] [Abstract][Full Text] [Related]
3. Interaction of cremophor EL with human plasma. Kongshaug M; Cheng LS; Moan J; Rimington C Int J Biochem; 1991; 23(4):473-8. PubMed ID: 2015955 [TBL] [Abstract][Full Text] [Related]
4. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858 [TBL] [Abstract][Full Text] [Related]
5. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. Kessel D; Woodburn K; Decker D; Sykes E Oncol Res; 1995; 7(5):207-12. PubMed ID: 8534926 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of lipoprotein fractionation from 275 or 350 microliter of serum by ultracentrifugation and polyanion-precipitation. Widhalm K; Strobl W; Weninger M Artery; 1980; 8(2):199-204. PubMed ID: 7458687 [No Abstract] [Full Text] [Related]
7. The alteration of plasma lipoproteins by cremophor EL. Woodburn K; Kessel D J Photochem Photobiol B; 1994 Mar; 22(3):197-201. PubMed ID: 8014752 [TBL] [Abstract][Full Text] [Related]
8. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099 [TBL] [Abstract][Full Text] [Related]
9. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. Szebeni J; Muggia FM; Alving CR J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816 [TBL] [Abstract][Full Text] [Related]
10. Composition and electrophoretic mobility of plasma lipoproteins of dromedary camels (Camelus dromedarius). Asadi F; Shahriari A; Asadian P; Pourkabir M; Samadaei M Am J Vet Res; 2008 Jul; 69(7):880-5. PubMed ID: 18593238 [TBL] [Abstract][Full Text] [Related]
11. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Nygren P; Csoka K; Jonsson B; Fridborg H; Bergh J; Hagberg H; Glimelius B; Brodin O; Tholander B; Kreuger A Br J Cancer; 1995 Mar; 71(3):478-81. PubMed ID: 7880727 [TBL] [Abstract][Full Text] [Related]
12. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361 [TBL] [Abstract][Full Text] [Related]
13. Preferential binding of chlordecone to the protein and high density lipoprotein fractions of plasma from humans and other species. Soine PJ; Blanke RV; Guzelian PS; Schwartz CC J Toxicol Environ Health; 1982 Jan; 9(1):107-18. PubMed ID: 6174734 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Fjällskog ML; Frii L; Bergh J Eur J Cancer; 1994; 30A(5):687-90. PubMed ID: 7915908 [TBL] [Abstract][Full Text] [Related]
15. Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): role of the solvent Cremophor EL/ethanol. Cordes N; Plasswilm L Anticancer Res; 1998; 18(3A):1851-7. PubMed ID: 9673415 [TBL] [Abstract][Full Text] [Related]
16. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. Theis JG; Liau-Chu M; Chan HS; Doyle J; Greenberg ML; Koren G J Clin Oncol; 1995 Oct; 13(10):2508-16. PubMed ID: 7595701 [TBL] [Abstract][Full Text] [Related]
17. Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA. Ilinskaya AN; Clogston JD; McNeil SE; Dobrovolskaia MA Nanomedicine; 2015 Nov; 11(8):1925-38. PubMed ID: 26282378 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine. Liau-Chu M; Theis JG; Koren G Ann Pharmacother; 1997 Nov; 31(11):1287-91. PubMed ID: 9391679 [TBL] [Abstract][Full Text] [Related]
20. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]